Gongwin Biopharm Holdings Co Ltd

Gongwin Biopharm's capital structure is characterized by a low debt-to-equity ratio of 0.05, indicating a conservative leverage profile. The company holds significant liquidity with cash and equivalents amounting to TWD 506.41 million, which is 18.1% of total assets. The current ratio of 10.36 suggests strong short-term liquidity, well above the industry median for biotechnology firms. However, the company's operating cash flow is negative at TWD -135.75 million, and free cash flow is also negative at TWD -112.38 million, reflecting ongoing R&D and operational costs. Profitability metrics are weak, with a return on equity of -4.51% and a return on assets of -4.08%, both significantly below the industry median for biotechnology firms. The company reported a net loss of TWD -114.13 million and an operating loss of TWD -207.29 million in the latest period. These results are consistent with the high R&D intensity typical of early-stage biopharmaceutical companies. The company's revenue is concentrated in a single business segment focused on anti-cancer medicine, with no disclosed geographic revenue breakdown. This lack of diversification increases exposure to regulatory and clinical trial risks. The company's cross-regional platform spans Taiwan, China Mainland, and the United States, but revenue concentration data is not available to assess geographic risk. Gongwin Biopharm's growth trajectory is speculative, with no disclosed revenue growth in the latest period. The company is in the early stages of product development, with several candidates in clinical trials. The outlook for the current fiscal year is uncertain, with no numeric delta provided, and the next fiscal year outlook is similarly undefined. The company's capital expenditure of TWD -2.46 million is minimal, suggesting limited near-term expansion plans. Risk factors include the high R&D costs and regulatory hurdles typical of the biotechnology industry. The company has no immediate filing-based liquidity or dilution flags, and dilution potential is assessed as low. However, the company's negative operating and free cash flows suggest a reliance on external financing, which could increase dilution risk in the future. Recent events include the ongoing development of PTS100 for liver cancer and PTS302 for lung cancer. No recent filings or transcripts were provided in the input data to detail specific clinical trial progress or regulatory submissions.